A Study to Compare the Immune Response and Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine Compared to GSK Biologicals Adjuvanted Hepatitis B Vaccine in Pre-Dialysis and Dialysis Patients Who Have Not Been Exposed to Hepatitis B.
A Multicentric, Randomised Study Comparing the Immunogenicity and Safety of Henogen's Adjuvanted Hepatitis B Vaccine Given at 0, 1, 6 Months to That of GSK Biologicals' Adjuvanted Hepatitis B Vaccine Given at 0, 1, 2, 6 Moths in Pre-Dialysis, and Dialysis Patients Who Are Hepatitis B Naive.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
ATH, Belgium, 7800
- RHMS La Madeleine ATH
-
Aalst, Belgium, 9300
- O.L.Vrouwziekenhuis Aalst
-
Baudour, Belgium, 7331
- RHMS Clinique Louis Caty Baudour
-
Bruxelles, Belgium, 1200
- Cliniques Universitaires Saint Luc
-
Bruxelles, Belgium, B-1020
- CHU Brugmann (site V Horta) Service de néphrologie
-
Bruxelles, Belgium
- ULB Hôpital Erasme Département de Néphrologie
-
Bruxelles, Belgium, 1090
- AZ -VUB Dienst Nefrologie
-
Charleroi, Belgium, 6000
- CHU Hôpital civil de
-
Edegem, Belgium, B-2650
- UZ AntwerpenDienst nefrologie
-
Gent, Belgium, 9000
- UZ Gent
-
La Louvière, Belgium, 7100
- CHU Tivoli
-
Leuven, Belgium, 3000
- UZ Gasthuisberg Leuven Nierziekten
-
Montigny le tilleul, Belgium, 6110
- CHU Andre VESALE
-
Tournai, Belgium, 7500
- RHMS TournayService de néphrologie
-
-
-
-
-
Jihlava, Czech Republic, 59586 33
- Dept. of Heamodialysis Hospital JihlavaVrchlického
-
Liberec, Czech Republic, 46063
- Regional Hospital Liberec
-
Ostrava - Poruba, Czech Republic, 1790708 52
- Infection Diseases and AIDS Treatment ClinicUniversity Hospital with Outpatient Clinic
-
Prague, Czech Republic, 169 00
- Dept. of Internal Medicine StrahovSermirska 5
-
Usti nad Labem, Czech Republic, 401 13
- Masaryk´s Hospital Socialni pece 3316/12A
-
-
-
-
-
Budapest, Hungary, 1096
- St. István Hospital
-
Budapest, Hungary, 1085
- St. Rókus Hospital
-
Győr, Hungary, H-9023
- Petz Aladár Teaching Hospital Vasvári
-
Kistarcsa, Hungary, 2143
- Pest County Flór Ferenc Hospital
-
Szombathely, Hungary, 9700
- Vas and Szombathely County Markusovszky Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- A male or female subject 15 years of age or older at the time of the study entry.
- Written informed consent obtained from the subject/ from the parent or guardian of the subject.
- Seronegative for anti-HBs antibodies, anti-HBc antibodies and for HBsAg at screening.
- Pre-dialysis patients, peritoneal dialysis patients or haemodialysis patients.
- Non-childbearing potential female
Exclusion Criteria:
- Use of any investigational or non-registered drug or vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- Use of any registered vaccine within 7 days before the first dose of study vaccine.
- Previous vaccination against hepatitis B (whether or not the subject responded to the vaccine).
- History of hepatitis B infection.
- Known exposure to hepatitis B virus within 6 months.
- Use of immunoglobulins within six months preceding the first study vaccination.
- Immunosuppression caused by the administration of parenteral steroids or chemotherapy (oral steroids are allowed).
- Any confirmed or suspected human immunodeficiency virus (HIV) infection.
- A family history of congenital or hereditary immunodeficiency.
- History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.
- Acute disease at the time of enrolment. Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhoea, mild upper respiratory infection with or without low-grade febrile illness, i.e. oral/ axillary temperature < 37.5°C (or 37 °C in Czech Republic).
- Oral/axillary temperature superior or equal to 37.5°C (or 37 °C in Czech Republic).
- Pregnant or lactating female
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 1
Henogen HB vaccine
|
20µg, Month 0, 2 and 6
|
|
Active Comparator: 2
Fendrix vaccine
|
20 µg,Months 0, 1, 2 and 6
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Anti-HBs seroprotection rate at Month 2.
Time Frame: Month 0 and 2
|
Month 0 and 2
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Anti-HBs antibody concentrations
Time Frame: Months 0, 1, 2, 3, 6 and 7
|
Months 0, 1, 2, 3, 6 and 7
|
|
Anti-HBs seroprotection rates for all subjects.
Time Frame: Months 0, 1, 2, 3, 6 and 7
|
Months 0, 1, 2, 3, 6 and 7
|
|
Anti-HBs seropositivity rates for all subjects
Time Frame: Months 0, 1, 2, 3, 6 and 7
|
Months 0, 1, 2, 3, 6 and 7
|
|
Percentage of subjects with anti-HBs antibody concentrations equal or greater than 100 mIU/ml for all subjects.
Time Frame: Months 0, 1, 2, 3, 6 and 7
|
Months 0, 1, 2, 3, 6 and 7
|
|
Anti-HBs geometric mean concentrations calculated for all subjects.
Time Frame: Months 0, 1, 2, 3, 6 and 7
|
Months 0, 1, 2, 3, 6 and 7
|
|
Anti-RF-1 seropositivity rates (defined as the percentage of subjects with anti-RF-1 like antibody concentrations superior or equal to 33 EU/ml, the assay cut-off) in a random subset of 50 subjects per group.
Time Frame: Months 0 and 7
|
Months 0 and 7
|
|
Anti-RF-1 like antibody geometric mean concentration in a random subset of 50 subjects per group.
Time Frame: Month 0 and 7
|
Month 0 and 7
|
|
Occurrence and intensity of solicited local signs and symptoms, as well as occurrence, intensity and relationship to vaccination of solicited general signs and symptoms during a 4-day follow-up (i.e. Day 0 to Day 3) after each vaccination and overall.
Time Frame: Month 0, 1, 2, 3, 6 and 7
|
Month 0, 1, 2, 3, 6 and 7
|
|
Occurrence, intensity and relationship to vaccination of unsolicited symptoms reported during the 31-day (Day 0 to Day 30) follow-up period after each vaccination and overall.
Time Frame: Month 0, 1, 2, 3, 6 and 7
|
Month 0, 1, 2, 3, 6 and 7
|
|
Occurrence, intensity and relationship to vaccination of all serious adverse events (SAEs) up to Month 7.
Time Frame: Month 0 to 7
|
Month 0 to 7
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Christian Tielemans, MD, PhD, ULB Hôpital Erasme Département de Néphrologie
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HN014/HBV-001 (105757)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.